Navigation Links
Amilpar Acquires ESHO
Date:2/1/2010

RIO DE JANEIRO, Feb. 1 /PRNewswire-FirstCall/ -- Amil Participacoes S.A. (Bovespa: AMIL3) ("Amilpar"), in accordance with CVM (the Brazilian Securities and Exchange Commission) Instruction 358/02, informs that today it exercised the option to purchase 100% of ESHO - Empresa de Servicos Hospitalares Ltda, as established in the Management and Hospital Call Option Agreement, signed on October 18, 2007, in the total amount of R$ 60.1 million, set after the auditing process, according to the decision taken by Amilpar's Board of Directors, in a meeting held on November 9, 2009.

The payment will be made in 48 monthly and successive installments, adjusted by the CDI (average interbank deposit rate in Brazil), the first installment with maturity on February 18 and the other installments on the 15th day of each month.

The main assets that comprise ESHO are the three hospitals which were already managed by Amilpar, as established in the Management and Hospital Call Option Agreement, and this acquisition is the accomplishment of the compromise made by Amilpar at the time of its IPO. Hospital information:

(i) CardioTrauma Hospital, located at Rua Farme de Amoedo, Ipanema, in the city and state of Rio de Janeiro, has 46 beds;

(ii) Mario Lioni Hospital, located at Rua Ana Neri, Bairro Vinte e Cinco de Agosto, Duque de Caxias, in the state of Rio de Janeiro, has 120 beds;

(iii) Hospital Paulistano, located at Rua Martiniano de Carvalho, the corner with Rua Pio XII, Bairro Liberdade, in the city and state of Sao Paulo, has 211 beds.

    To access the press release, visit our website at www.amilpar.com.br/ir.

    IR Contact
    Erwin Kleuser
    Investor Relations Officer
    Phone: +55 (21) 3805-1155
    invest@amil.com.br
    www.amilpar.com.br/ir

SOURCE Amil Participacoes S.A.

RELATED LINKS
http://www.amilpar.com.br/ir

'/>"/>

SOURCE Amil Participacoes S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Amilpar - Relevant Fact - Public Offer Result
2. Amilpar - Press Release
3. Amilpar - Distribution of Interest on Capital Stock
4. Amilpar - Relevant Fact
5. Amilpar - Press Release - Commercial Papers
6. Amilpar - Relevant Fact - Public Offer
7. Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09
8. Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009
9. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
10. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
11. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: